DRREDDY / Q1-FY26 / claim-ledger

Audit the questions that mattered.

Dr. Reddy's Laboratories · Analyst questions, management answers, and the quality of the response where the ledger is available.

Research layer active

ConCallIQ research layer

Signal, with the source still visible.

Use the controls below to narrow the view, then follow the evidence into the next layer of context.

WatchQ1-FY26 · 2025-07-30Back to quarter ↗

Questions audited

11

Answered directly

86%

Numeric claims

5

Consistency

contradicted

Question ledger

What was answered, and how?

Amey Chalke · JM Financial

direct

US base business QoQ performance and FY26 outlook

the base business in the U.S. decreased. It's primarily timing. ... Overall, the base business, the way I see it, is going to be flat to single-digit growth like we normally are discussing.

Amey Chalke · JM Financial

direct

Revlimid trajectory for upcoming quarters

What you should anticipate is one more quarter, give or take, in the range of what you have today and relatively much less in Q3. After that, some leftover, and that's it.

Amey Chalke · JM Financial

direct

Semaglutide launch timeline in RoW markets

the launch in the rest of the countries during calendar 2026. ... The key will be India, Brazil, Turkey, and products like that will be after March of 2026.

Neha Manpuria · Bank of America

direct

US pipeline: SEMA timeline, high-value launches, PAI inspection

Gearing to get approval of the product somewhere between the end of October to the beginning of November. ... we did not take into account a very significant, let's say, out-of-the-ordinary launch.

Neha Manpuria · Bank of America

direct

Gross margin trend and SG&A cost outlook

As far as gross margin is concerned, I think at least for this year it would be in similar levels. ... As far as SG&A is concerned, I think we, even for the full year basis, it should be in the zone of 28%-29% zone, not at 30%.

Damayanti Kiray · HSBC

partial

Lenalidomide Q2 sales magnitude and pricing pressure

overall, let's call it similar magnitude. I will not say the same, but similar magnitude.

Damayanti Kiray · HSBC

direct

Semaglutide capacity expansion at ViaJag and timing

The launches that will happen in FY26 and FY27 will not be out of ViaJag. It will be with our partner ... about INR 12 million in FY27.

Madhav Marda · Fidelity International

direct

Biosimilar abatacept phase 3 trial progress and outcome timeline

So far, so good. The readout is November 25, which is as expected in accordance to the timelines.

Madhav Marda · Fidelity International

partial

Cost-saving potential and R&D spend quantum

there are discretionary costs between R&D, SG&A that can be 500 basis points, 600 basis points that we are planning to adjust.

Harith Ahmed · Avendus Park

partial

Generic Liraglutide filing status and launch timeline

We are planning to launch it also in the next coming quarters. ... with Saxenda, we are going to be first to market or some of the first to market in some of them.

Bino Pathiparampil · Elara Capital

direct

PSAI gross margin decline reason

the reason for that is some of the demand products for the U.S. are also being back integrated. ... It's actually a very healthy business and it's growing.

Saion Mukherjee · Nomura

direct

PLI income for the quarter

Not for this quarter. For the full year also, is almost, let me put it, I think is very small value is there. Not very big.